Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: Evaluation with inductively coupled plasma mass spectrometry (ICP-MS)

Magnetic Resonance Imaging

Volumn 31, Issue 8, 2013, Pages 1412-1417

  Sato, Tomohiro ^a   Ito, Katsuyoshi ^a   Tamada, Tsutomu ^a   Kanki, Akihiko ^a   Watanabe, Shigeru ^a   Nishimura, Hirotake ^a   Tanimoto, Daigo ^a   Higashi, Hiroki ^a   Yamamoto, Akira ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Gadolinium (Gd) based contrast agents (GBCAs); Gd DTPA BMA; Gd EOB DTPA; Gd HP DO3A; Inductively coupled plasma mass spectrometry (ICP MS); Nephrogenic systemic fibrosis (NSF)

Indexed keywords

GADOLINIUM; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM; HEART; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY EXAMINATION; KIDNEY FAILURE; LUNG EXAMINATION; MALE; MASS SPECTROMETRY; MUSCLE LEVEL; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN EXAMINATION; SPLEEN EXAMINATION; TISSUE DISTRIBUTION;

RATTUS;

GADOLINIUM (GD)-BASED CONTRAST AGENTS (GBCAS); GD-DTPA-BMA; GD-EOB-DTPA; GD-HP-DO3A; INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY (ICP-MS); NEPHROGENIC SYSTEMIC FIBROSIS (NSF);

ANIMALS; CONTRAST MEDIA; GADOLINIUM; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC CLEARANCE RATE; NEPHROGENIC FIBROSING DERMOPATHY; ORGAN SPECIFICITY; RATS; RATS, WISTAR; RENAL INSUFFICIENCY; RISK ASSESSMENT; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TISSUE DISTRIBUTION;

EID: 84883743139     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2013.03.025     Document Type: Article

References (23)

1. Pietsch H., Lengsfeld P., Steger-Hartmann T., et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 2009, 44:226-233.
2. Sieber M.A., Pietsch H. Validity of the animal models for nephrogenic systemic fibrosis. Invest Radiol 2008, 43:338.
3. Knopp M.V., Balzer T., Esser M., Kashanian F.K., Paul P., Niendorf H.P. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 2006, 41:491-499.
4. Bourrinet P., Martel E., El Amrani A.I., et al. Cardiovascular safety of gadoterate meglumine (Gd-DOTA). Invest Radiol 2007, 42:63-77.
5. Herborn C.U., Honold E., Wolf M., et al. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 2007, 42:58-62.
6. Caravan P., Ellison J.J., McMurry T.J., Lauffer R.B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999, 99:2293-2352.
7. Deo A., Fogel M., Cowper S.E. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007, 2:264-267.
8. Lauenstein T.C., Salman K., Morreira R., et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imag 2007, 26:1198-1203.
9. Shabana W.M., Cohan R.H., Ellis J.H., et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 2008, 190:736-741.
10. Prince M.R., Zhang H., Morris M., et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008, 248:807-816.
11. Wertman R., Altun E., Martin D.R., et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008, 248:799-806.
12. Runge V.M. Safety of magnetic resonance contrast media. Top Magn Reson Imaging 2001, 12:309-314.
13. Thomsen H.S. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am 2009, 47:827-831.
14. Leiner T., Kucharczyk W. Special issue: nephrogenic systemic fibrosis. J Magn Reson Imaging 2009, 30:1233-1235.
15. Penfield J.G., Reilly R.F. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?. Semin Dial 2008, 21:129-134.
16. Broome D.R., Girguis M.S., Baron P.W., Cottrell A.C., Kjellin I., Kirk G.A. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007, 188:586-592.
17. Rydahl C., Thomsen H.S., Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008, 43:141-144.
18. Grant D., Johnsen H., Juelsrud A., Lovhaug D. Effects of gadolinium contrast agents in naive and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol 2009, 50:156-169.
19. Sieber M.A., Pietsch H., Walter J., et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008, 43:65-75.
20. Morcos S.K. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium-based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?. Br J Radiol 2007, 80:73-76.
21. Morcos S.K. Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?. Eur Radiol 2011, 21:496-500.
22. Weinmann H.J., Schuhmann-Giampieri G., Schmitt-Willich H., et al. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991, 22(2):233-237.
23. Hamm B., Staks T., Muhler A. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995, 195:785-792.